Skip to main content
Home
  • About Us
    • About Us
    • Mission & Values
    • Leadership
    • News
    • Careers
    • Partnerships
    • Support
    • Achievements
  • For Researchers
    • Clinical Trials
      • Allergy & Asthma
      • Autoimmune Disease
      • Transplantation
      • Type 1 Diabetes
    • Core Facilities
    • Lab Protocols
      • ITN Protocols
      • T1D Preclinical Consortium
    • Policies
      • Publications Policy
    • Proposals
      • Submit Proposal
      • Current RFPs
      • Past RFPs
    • Publications
    • TrialShare
    • Strategic Plans
      • Allergy
      • Autoimmune Disease
        • Type 1 Diabetes
      • Transplantation
  • For Patients
    • Allergy & Asthma
    • Autoimmune Disease
    • Transplantation
      • Kidney
      • Liver
    • Type 1 Diabetes
    • Clinical Trial Info
  • TrialShare
  • Contact
    • Contact Us
      • BRI - Seattle Office
      • UCSF - San Francisco Office
    • Media Inquiries
Home

Secondary links

  • Home
  • TrialShare
  • Member Portal
  • About Us
    • About Us
    • Mission & Values
    • Leadership
    • News
    • Careers
    • Partnerships
    • Support
    • Achievements
  • For Researchers
    • Clinical Trials
    • Core Facilities
    • Lab Protocols
    • Policies
    • Proposals
    • Publications
    • TrialShare
    • Strategic Plans
  • For Patients
    • Allergy & Asthma
    • Autoimmune Disease
    • Transplantation
    • Type 1 Diabetes
    • Clinical Trial Info
  • TrialShare
  • Contact
    • Contact Us
    • Media Inquiries

Primary links

  • Clinical Trials
    • Allergy & Asthma
    • Autoimmune Disease
    • Transplantation
    • Type 1 Diabetes
  • Core Facilities
  • Lab Protocols
    • ITN Protocols
    • T1D Preclinical Consortium
  • Policies
  • Proposals
  • Publications
  • TrialShare
  • Strategic Plans

ITN/JDRF Type 1 Diabetes Preclinical Consortium Protocols

The Immune Tolerance Network (ITN) provides the standard operating procedures and protocols developed by ITN personnel and collaborators for use by the research community. Please note that no technical support is available. All works are licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 2.5 License. 


Detailed Protocols

The following are the standard operating procedures and protocols developed and used by the ITN/JDRF Type 1 Diabetes (T1D) Preclinical Consortium. The ITN/JDRF T1D Preclinical Consortium consists of four, independent, geographically diverse laboratories with the goal of generating reproducible data using a single protocol and standardized operating procedures. The consortium conducts pre-clinical screening for strategic combinations of agents to demonstrate safety and efficacy before moving into clinical trials.

Other

ITN2-001
Subsequent and Simultaneous Anti-CD3 and Anti-IL-1 Therapy
v.08
ITN3-001
Anti-CD3 plus IL-1 Trap Pilot Study
v.02
ITN5P-001
Determination of optimal IL-2 dosing for maintaining antigen-specific Tregs in new onset diabetic NOD mice
v.09.1
ITN5P-002
Thawing Mouse Treg Cell Stocks
v.02
ITN5P-003
Mouse Stool Sample Collection and Storage
v.01
ITN5P-004
Collection and Freezing of Fresh NOD Pancreas Tissue in OCT for Cryostat Sectioning
v.01
ITN5P-005
Analysis of Treg and Teffector Cell Populations by Flow Cytometry
v.01
NOD-0001
Subject Identificiation, Inclusion/Exclusion Criteria, and Study Enrollment
v.01
NOD-0002
Allocation of Study Subjects to Treatment Groups
v.02
NOD-0003
Study Endpoints
v.02
NOD-0005
Blood Glucose Monitoring
v.02
NOD-0006
Treatment Groups
v.02
NOD-0009
Blood Collection
v.03
NOD-0010
Schedule of Assessments
v.01
NOD-0011
Mouse Necropsy for Pancreas and Related Organs
v.01
NOD-0014
Assessment at Study Endpoint
v.01

The Immune Tolerance Network and is sponsored by the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health.

National Institute of Allergy and Infectious Diseases

Footer

  • Home
  • Sponsors
  • Careers
  • Contact
  • Search

© 2021 Immune Tolerance Network

  • Privacy
  • Terms of Use
  • Accessibility